Fezagepras sodium NEW
| Price | $36 | $88 | $143 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-22 |
Product Details
| Product Name: Fezagepras sodium | CAS No.: 1254472-97-3 |
| Purity: 99.59% | Supply Ability: 10g |
| Release date: 2025/07/22 |
Product Introduction
Bioactivity
| Name | Fezagepras sodium |
| Description | Fezagepras sodium (Setogepram sodium salt) is an orally active GPR40 agonist and is an antagonist or inverse agonist for GPR84, with anti-fibrotic, anti-inflammatory and anti-proliferative actions. |
| In vitro | PBI-4050 inhibited kidney macrophage infiltration, oxidative stress, and TGF-β-mediated fibrotic signaling pathways, and it also protected against the development of tubulointerstitial fibrosis.?To confirm a direct antiinflammatory/antifibrotic effect in the kidney, further studies with a nondiabetic model of EGFR-mediated proximal tubule activation confirmed that PBI-4050 dramatically decreased the development of the associated tubulointerstitial injury and macrophage infiltration[1]. |
| In vivo | eNOS-/- db/db mice were treated with PBI-4050 from 8-20 weeks of age (early treatment) or from 16-24 weeks of age (late treatment).?PBI-4050 treatment ameliorated the fasting hyperglycemia and abnormal glucose tolerance tests seen in vehicle-treated mice.?In addition, PBI-4050 preserved (early treatment) or restored (late treatment) blood insulin levels and increased autophagy in islets.?PBI-4050 treatment led to significant improvements in lifespan in the diabetic mice.?Both early and late PBI-4050 treatment protected against progression of DN, as indicated by reduced histological glomerular injury and albuminuria, slow decline of glomerular filtration rate, and loss of podocytes[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 90 mg/mL (394.29 mM), Sonication is recommended. DMSO : 60 mg/mL (262.86 mM), Sonication is recommended. |
| Keywords | Setogepram sodium | PBI-4050 sodium | GPR40 | Fezagepras sodium |
| Inhibitors Related | Vincamine | Monomethyl fumarate | Questiomycin A | 3-Hydroxyoctanoic Acid | Azathioprine | CRTh2 antagonist 2 | Benzyl nicotinate | 1-methoxycyclopropanecarboxylic acid | TUG-1375 | CAY10595 | Timapiprant | NF-56-EJ40 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Orally Active Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $48.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-15 | |
| $350.00/1KG |
VIP6Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2020-07-13 | |
| $60.00/1kg |
Hebei Zhuanglai Chemical Trading Co.,Ltd
|
2024-05-15 | ||
| $36.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY